Outlook Therapeutics, Inc.
OTLK
$1.45
$0.085.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 9.10% | -27.78% | -55.87% | -178.20% | 26.69% |
| Total Depreciation and Amortization | 85.88% | 157.69% | 13.96% | -36.76% | -62.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -374.47% | -15.48% | 257.23% | 1,141.60% | -12.01% |
| Change in Net Operating Assets | 236.64% | -163.49% | -203.02% | -1,853.31% | -252.80% |
| Cash from Operations | -41.66% | -60.09% | -59.46% | -20.45% | 13.71% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | -100.00% |
| Total Debt Repaid | 90.98% | 99.96% | 99.93% | 99.95% | 99.94% |
| Issuance of Common Stock | 986.02% | 99.08% | 112.65% | 132.92% | -80.57% |
| Repurchase of Common Stock | 66.11% | 66.11% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 100.00% | 55.18% |
| Cash from Financing | 1,112.38% | 23.20% | 30.51% | 84.26% | -86.08% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 88.91% | -241.19% | -121.91% | 124.33% | -135.73% |